Results 171 to 180 of about 183,641 (351)

Cross Talk between Angiotensin II Type 1 and Type 2 Receptors: Cellular Mechanism of Angiotensin Type 2 Receptor-Mediated Cell Growth Inhibition.

, 1999
Masatsugu Horiuchi, Meiko Hamai, Taixing Cui, Masaru Iwai, Yasuhiko Minokoshi   +4 more
openalex   +2 more sources

The Third Cytoplasmic Loop of the Angiotensin II Type 1 Receptor Exerts Differential Effects on Extracellular Signal–Regulated Kinase (ERK1/ERK2) and Apoptosis via Ras- and Rap1-Dependent Pathways [PDF]

, 2000
Judith Haendeler, Mari Ishida, László Hunyady, Bradford C. Berk   +3 more
openalex   +1 more source

Myocardial inflammation is associated with impaired mitochondrial oxidative capacity in ischaemic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1246-1255, April 2025.
Abstract Aims Myocardial inflammation and impaired mitochondrial oxidative capacity are hallmarks of heart failure (HF) pathophysiology. The extent of myocardial inflammation in patients suffering from ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and its association with mitochondrial energy metabolism are unknown.
Julius Borger, Elric Zweck, Constanze Moos, Patrick Horn, Fabian Voß, Heinz‐Peter Schultheiss, Jacob Eifer Møller, Udo Boeken, Hug Aubin, Artur Lichtenberg, Malte Kelm, Michael Roden, Amin Polzin, Ralf Westenfeld, Julia Szendroedi, Daniel Scheiber   +15 more
wiley   +1 more source

Blockade of Angiotensin II Receptor Type 1 Abolishes the Erythropoietin Response to Exercise. [PDF]

Function (Oxf)
Guo M, Montero D.
europepmc   +1 more source

Alterations in sarcoplasmic reticulum and angiotensin II receptor type 1 gene expression in spontaneously hypertensive rat hearts.

Japanese circulation journal, 1999
Y. Arata, E. Geshi, A. Nomizo, S. Aoki, T. Katagiri   +4 more
semanticscholar   +1 more source

Projecting the benefit of vericiguat in PARADIGM‐HF and DAPA‐HF populations: Insights from the VICTORIA trial

ESC Heart Failure, Volume 12, Issue 2, Page 1479-1484, April 2025.
Abstract Aims The VICTORIA trial demonstrated a significant reduction in the primary composite outcome of heart failure (HF) hospitalization or cardiovascular death with vericiguat relative to placebo in high‐risk HF. This study aimed to contextualize treatment effects of vericiguat in populations with varying risk profiles simulated from the PARADIGM ...
Veraprapas Kittipibul, Robert J. Mentz, Rebecca Young, Javed Butler, Justin A. Ezekowitz, Carolyn S.P. Lam, Piotr Ponikowski, Adriaan Voors, Stefano Corda, Ciaran McMullan, Christopher M. O'Connor, Kevin J. Anstrom, Paul W. Armstrong, for the VICTORIA Study Group   +13 more
wiley   +1 more source

Engineering the angiotensin II type 1 receptor for structural studies

, 2015
Jennifer A. Thomas
openalex   +2 more sources

Effect of systemic administration of valsartan, an angiotensin II type 1 receptor blocker, on retinal circulation in healthy humans [PDF]

, 2008
Taiji Nagaoka, Atsushi Takahashi, Eriko Sato, Harumasa Yokota, Naohiro Izumi, Akitoshi Yoshida   +5 more
openalex   +1 more source

Angiotensin II receptor, type 1 (AGTR1; AT1) [PDF]

Science-Business eXchange, 2008
openaire   +1 more source

Considerations for drug trials in hypertrophic cardiomyopathy

ESC Heart Failure, Volume 12, Issue 2, Page 1095-1112, April 2025.
Abstract Hypertrophic cardiomyopathy (HCM) is a heterogeneous condition with potentially serious manifestations. Management has traditionally comprised therapies to palliate symptoms and implantable cardioverter‐defibrillators to prevent sudden cardiac death. The need for disease‐modifying therapies has been recognized for decades.
John P. Farrant, Matthias Schmitt, Anna B. Reid, Clifford J. Garratt, William G. Newman, Aneil Malhotra, Rhys Beynon, Masliza Mahmod, Betty Raman, Robert M. Cooper, Dana Dawson, Thomas Green, Sanjay K. Prasad, Anvesha Singh, Susanna Dodd, Hugh Watkins, Stefan Neubauer, Christopher A. Miller   +17 more
wiley   +1 more source